Cosmo Pharmaceuticals N.V.

The pharmaceutical market is notoriously difficult to predict. Drug developers and the analysts who cover them must navigate a landscape shaped by geopolitical shifts, financial pressures and regulato

It is well known that the pharmaceutical industry is unpredictable. Both drug developers themselves and the brokers covering them must do their best to try and predict the performance of their assets

Eli Lilly and Italfarmaco were due this week to appear before the European Medicines Agency’s human medicines committee, the CHMP, for oral explanations as to why their respective drugs, donanemab and

Glenmark Pharmaceuticals Limited ’s revenue mix by region appears set for an overhaul, with Europe expected to match the US, a market where the Indian firm has been struggling to regain momentum. At t